Scientists hope to erase high cholesterol for life with a single gene snip.

Groundbreaking scientific trials are demonstrating the potential for gene-editing therapies to offer a permanent solution for high cholesterol, aiming to eliminate the need for lifelong medication. Recent Phase 1 studies have shown that a single infusion of these experimental treatments can safely and significantly reduce harmful cholesterol levels. For instance, a CRISPR-Cas9 therapy targeting the ANGPTL3 gene has shown to lower LDL ("bad") cholesterol by over 50% and triglycerides by nearly 50% one year after treatment in patients with medication-resistant lipid disorders.

Another gene-editing approach, using base-editing technology to inactivate the PCSK9 gene, has also yielded promising results, with some patients experiencing a reduction of up to 62% in LDL cholesterol. These innovative therapies work by modifying specific genes in the liver that regulate cholesterol, mimicking natural genetic mutations found in individuals with very low cholesterol and reduced heart disease risk.

While these initial trials involved small patient groups and focused on safety and early efficacy, the sustained reductions observed are fostering optimism among scientists and clinicians. Researchers believe these "one-and-done" treatments could revolutionize cardiovascular care by providing a durable solution for millions who struggle with managing high cholesterol through daily pills or injections, though long-term safety monitoring, often up to 15 years, is a standard recommendation for such CRISPR-based therapies.